Vireo Growth (VREOF) Asset Writedowns and Impairment (2022 - 2026)
Vireo Growth (VREOF) posted Asset Writedowns and Impairment of $300000.0 for Q1 2026, down 86.88% sequentially from $2.3 million in Q4 2025, and down 25.0% YoY from $400000.0 in Q1 2025.
Vireo Growth (VREOF) Asset Writedowns and Impairment (2022 - 2026) Analysis & Trends
Vireo Growth has reported Asset Writedowns and Impairment for 4 years, with the latest figure at $300000.0 in Q1 2026.
- Quarterly Asset Writedowns and Impairment fell 25.0% year-over-year to $300000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.4 million (up 274.14% YoY) and the FY2025 annual result came in at $2.6 million, up 784.35% from the prior year.
- Asset Writedowns and Impairment declined to $300000.0 in Q1 2026 per VREOF's latest filing, from $2.3 million in the prior quarter.
- Over five years, Asset Writedowns and Impairment peaked at $5.3 million in Q1 2022 and troughed at -$304000.0 in Q1 2024.
- A 4-year average of $965084.7 and a median of $393000.0 in 2024 frame the typical range for Asset Writedowns and Impairment.
- The widest YoY moves for Asset Writedowns and Impairment: up 3518.72% in 2025, down 651.58% in 2025.
- Over 4 years, Asset Writedowns and Impairment stood at $1.1 million in 2022, then tumbled by 94.36% to $63182.0 in 2024, then surged by 3518.72% to $2.3 million in 2025, then sank by 86.88% to $300000.0 in 2026.
- According to Business Quant data, Asset Writedowns and Impairment over the past three periods registered $300000.0, $2.3 million, and $996485.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.89 Bn | 42.93 Bn | - |
| 2 | Teva Pharmaceutical Industries | 42.98 Bn | 39.33 Bn | 2.15 Bn |
| 3 | Zoetis | 31.54 Bn | 29.86 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.15 Bn | 19.48 Bn | 683.80 Mn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.56 Bn | 15.17 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.74 Bn | 11.21 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.95 Bn | - |
| 10 | Vireo Growth | 491.44 Mn | 349.14 Mn | 95.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 300,000.00 |
| Mar 31, 2026 | 300,000.00 |
| Dec 31, 2025 | 2.29 Mn |
| Dec 31, 2025 | 2.29 Mn |
| Sep 30, 2025 | 996,485.00 |
| Sep 30, 2025 | 996,485.00 |
| Jun 30, 2025 | -226,149.00 |
| Jun 30, 2025 | -226,149.00 |
| Mar 31, 2025 | 400,000.00 |
| Mar 31, 2025 | 400,000.00 |
| Dec 31, 2024 | 63,182.00 |
| Dec 31, 2024 | 63,182.00 |
| Sep 30, 2024 | 393,000.00 |
| Sep 30, 2024 | 393,000.00 |
| Jun 30, 2024 | 41,000.00 |
| Jun 30, 2024 | 41,000.00 |
| Mar 31, 2024 | -304,000.00 |
| Mar 31, 2024 | -304,000.00 |
| Dec 31, 2022 | 1.12 Mn |
| Dec 31, 2022 | 1.12 Mn |